YC-1: Soluble Guanylyl Cyclase Activator & HIF-1α Inhibitor for Cancer and Hypoxia Research

Executive Summary: YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a crystalline small molecule that activates soluble guanylyl cyclase (sGC) and inhibits hypoxia-inducible factor-1α (HIF-1α) at the post-transcriptional level (APExBIO). YC-1 demonstrates an IC50 of 1.2 µM for hypoxia-induced HIF-1 transcriptional activity in vitro, making it a potent tool for modulating hypoxia signaling [APExBIO]. In vivo, YC-1 reduces tumor size, vascularization, and expression of HIF-1α target genes under hypoxic conditions. The compound is soluble at ≥30.4 mg/mL in DMSO and ≥16.2 mg/mL in ethanol, but insoluble in water [APExBIO]. Its use is strictly for research purposes, with purity typically ≥98% and rapid solution degradation upon storage. YC-1 is supplied by APExBIO and is central to workflows in apoptosis, tumor angiogenesis, and mitochondrial quality control research (Optimizing Cancer and Hypoxia Research with YC-1).

Biological Rationale

YC-1 is employed in research to dissect the oxygen-sensing pathway and hypoxia signaling mechanisms in cancer and vascular biology. HIF-1α is a transcription factor that regulates genes involved in tumor survival, angiogenesis, and adaptation to hypoxic stress. Under low oxygen, HIF-1α accumulates and activates gene expression that enables tumor growth and metastasis. YC-1 was initially developed to inhibit HIF-1α, blocking its transcriptional activity and thus impairing tumor adaptation to hypoxia [APExBIO]. It also activates sGC, a key enzyme in the cGMP signaling pathway, which modulates vascular tone and platelet aggregation. YC-1’s dual action allows researchers to study the interplay between oxygen sensing, angiogenesis, and cGMP-mediated signaling in cancer, cardiovascular, and hypoxia-related models. For further context, this article extends the mechanistic focus presented in YC-1: Mechanistic Depth and Translational Promise in Hypoxia by detailing quantitative benchmarks and experimental integration steps.

Mechanism of Action of YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol

YC-1 acts via two distinct but intersecting mechanisms:

• HIF-1α Inhibition: YC-1 inhibits HIF-1α protein accumulation by interfering with its post-transcriptional regulation. This prevents HIF-1α from activating hypoxia-induced genes involved in angiogenesis, glycolysis, and cell survival.
• Soluble Guanylyl Cyclase Activation: YC-1 directly activates sGC, increasing intracellular cGMP levels. Enhanced cGMP signaling leads to vasodilation and inhibition of platelet aggregation, relevant for vascular and circulation research.

Notably, the anticancer effect of YC-1 is primarily attributed to HIF-1α inhibition rather than sGC activation. Its IC50 for hypoxia-induced HIF-1 transcriptional activity is 1.2 µM, established under defined in vitro hypoxic culture conditions [APExBIO]. Compared to classic sGC activators or HIF-1α inhibitors, YC-1’s dual mechanism enables unique crosstalk studies between oxygen sensing and cGMP pathways (YC-1: Mechanistic Insight in Translational Research), thereby extending the comparative analysis offered in previous reviews.

Evidence & Benchmarks

• YC-1 suppresses HIF-1α protein expression and downstream gene transcription in multiple tumor cell lines exposed to hypoxia (APExBIO, https://www.apexbt.com/yc-1.html).
• In vivo administration of YC-1 leads to smaller and less vascularized tumors, with quantifiable reductions in HIF-1α target gene expression (APExBIO, https://www.apexbt.com/yc-1.html).
• Platelet aggregation and vascular contraction are inhibited by YC-1 through sGC activation and increased cGMP signaling (Elama et al., https://doi.org/10.1016/j.saa.2021.120420).
• YC-1’s IC50 for hypoxia-induced HIF-1 transcriptional activity is 1.2 µM; this value is established in cell-based luciferase reporter assays under standard hypoxic (1% O2) conditions (APExBIO, https://www.apexbt.com/yc-1.html).
• Solubility benchmarks: ≥30.4 mg/mL in DMSO, ≥16.2 mg/mL in ethanol, insoluble in water; purity ≥98% (APExBIO, https://www.apexbt.com/yc-1.html).

Applications, Limits & Misconceptions

YC-1 is used for:

• Studying hypoxia signaling pathways in cancer, vascular, and mitochondrial research.
• Dissecting the cGMP signaling cascade in vascular biology and platelet function.
• Evaluating tumor angiogenesis inhibition and apoptosis under hypoxic stress.

However, the utility of YC-1 is limited by its rapid degradation in solution and insolubility in water. It is not suitable for diagnostic or clinical use. For a strategic roadmap on integrating YC-1 into translational workflows, see Revolutionizing Hypoxia and Cancer Research: Strategic De..., which is complemented here by explicit benchmark data and compatibility details.

Common Pitfalls or Misconceptions

• YC-1 is not a direct inhibitor of sGC; its anticancer effect is primarily via HIF-1α inhibition.
• Long-term storage of YC-1 solutions is not recommended due to rapid degradation; fresh solutions must be prepared for each experiment.
• YC-1 is insoluble in water; attempts to dissolve in aqueous buffers will fail and compromise activity.
• It is not validated for diagnostic or therapeutic use in humans or animals.
• cGMP signaling effects are cell-type and context dependent, requiring controls in each experimental system.

Workflow Integration & Parameters

For optimal use, dissolve YC-1 at concentrations up to 30.4 mg/mL in DMSO or 16.2 mg/mL in ethanol. Prepare fresh working solutions immediately prior to use. Store the crystalline solid at room temperature, protected from moisture. Use in vitro at 0.5–5 µM, adjusting to model and cell line. For HIF-1α inhibition studies, employ hypoxic (1% O2) conditions and validate with luciferase reporter assays. In vascular models, monitor cGMP accumulation and vasorelaxation endpoints. The B7641 kit from APExBIO provides analytically validated reference material. For advanced integration strategies, this article clarifies and updates the troubleshooting and comparative insights found in Optimizing Cancer and Hypoxia Research with YC-1.

Conclusion & Outlook

YC-1 is a rigorously benchmarked, dual-action small molecule for dissecting hypoxia and cGMP pathways in cancer and vascular biology research. Its defined molecular mechanism, high purity, and established in vitro and in vivo efficacy make it a gold standard for HIF-1α inhibition and sGC activation studies. Proper handling and workflow integration are essential to maximize reproducibility and data fidelity. As research advances, YC-1 will remain central to studies of tumor adaptation, angiogenesis, and oxygen-sensing mechanisms.